Drugs by condition
Drugs approved for chronic kidney disease
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
27
Still marketed, NDA or BLA
Drug classes
9
Novel drugs
14
New molecular entities and new biologics
In development
30
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for chronic kidney disease.
- Vafseo (Vadadustat) · Akebia NovelMar 27, 2024
- Xphozah (Tenapanor Hydrochloride) · Ardelyx INC NovelOct 17, 2023
- Inpefa (Sotagliflozin) · Lexicon Pharms INC NovelMay 26, 2023
- Furoscix (Furosemide) · Scpharmaceuticals Oct 7, 2022
- Korsuva (Difelikefalin Acetate) · Vifor Intl NovelBreakthrough therapyPriority reviewAug 23, 2021
All approved drugs for chronic kidney disease, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 56 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Sodium-Glucose Cotransporter 2 Inhibitor (4)
- Inpefa Sotagliflozin · Lexicon Pharms INC · 2023
- Jardiance Empagliflozin · Boehringer Ingelheim · 2014
- Synjardy Xr Empagliflozin, Metformin Hydrochloride · Boehringer Ingelheim · 2016
- Synjardy Empagliflozin, Metformin Hydrochloride · Boehringer Ingelheim · 2015
Parenteral Iron Replacement (3)
Vitamin D2 Analog (2)
- Zemplar Paricalcitol · Abbvie · 1998
- Paricalcitol Paricalcitol · Accord Hlthcare · 2016
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (1)
- Vafseo Vadadustat · Akebia · 2024
Nonsteroidal Mineralocorticoid-Receptor Antagonist (1)
- Kerendia Finerenone · Bayer Hlthcare · 2021
Erythropoiesis-stimulating Agent (1)
- Aranesp Darbepoetin Alfa · Amgen · 2001
Loop Diuretic (1)
- Furoscix Furosemide · Scpharmaceuticals · 2022
Phosphate Binder (1)
- Velphoro Ferric Oxyhydroxide · Vifor Fresenius · 2013
Class not listed in FDA's data (13)
- Xphozah Tenapanor Hydrochloride · Ardelyx INC · 2023
- Korsuva Difelikefalin Acetate · Vifor Intl · 2021
- Ozempic Semaglutide · Novo · 2017
- Parsabiv Etelcalcetide · Kai Pharms INC · 2017
- Farxiga Dapagliflozin · Astrazeneca Ab · 2014
- Mircera Methoxy Polyethylene Glycol-Epoetin Beta · Hoffman-La Roche · 2007
- Epogen/Procrit Epoetin Alfa · Amgen · 1989
- Monoferric Ferric Derisomaltose · Pharmacosmos · 2020
- Retacrit Epoetin Alfa-Epbx · Hospira INC · 2018
- Rayaldee Calcifediol · Eirgen · 2016
- Xigduo Xr Dapagliflozin, Metformin Hydrochloride · Astrazeneca Ab · 2014
- Auryxia Ferric Citrate · Keryx Biopharms · 2014
- Injectafer Ferric Carboxymaltose · Am Regent · 2013
Drugs in development for chronic kidney disease
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- AND017Phase 36 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- ESAErythropoiesis-Stimulating AgentPhase 33 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, Anemia of Chronic Kidney Disease
- HRS-1780Phase 33 trials
Shandong Suncadia Medicine Co., Ltd. · Chronic Kidney Disease, Uncontrolled or Resistant Hypertension, Primary Aldosteronism
- MT1013Phase 33 trials
Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis, Secondary Hyperparathyroidism, Chronic Kidney Disease
- PacibekitugTOUR006, PAC001Phase 33 trials
Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases
- PLS240upacicalcetPhase 33 trials
Pathalys Pharma · Secondary Hyperparathyroidism, Chronic Kidney Disease (CKD), End-stage Kidney Disease (ESKD)
- ABP-671Phase 32 trials
Atom Therapeutics Co., Ltd · Chronic Kidney Disease, Gout
- AP301Solnatide for reconstitution for forPhase 32 trials
Alebund Pharmaceuticals · Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease)
- QRX-3EseronatePhase 32 trials
Ebima Clifford Okundaye · Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
- rilparencelRenal Autologous Cell Therapy, REACTPhase 32 trials
Prokidney · Type 2 Diabetes Mellitus, Chronic Kidney Diseases, Type 1 Diabetes Mellitus
- RoxadustatFG-4592, ASP1517Phase 32 trials
Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes
- SAL0120Phase 32 trials
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Chronic Kidney Disease, Uncontrolled Hypertension, Resistant Hypertension
6 discontinued brand-name drugs whose label still names it
More on chronic kidney disease: recruiting trials · published research
Related in kidney and urology: IgA nephropathy · Overactive bladder · Enlarged prostate (BPH) · Erectile dysfunction
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.